List of APIs/Active Pharmaceutical Ingredients Companies with Phase 2 Active Clinical Trial - 11

Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.

Infusing Innovation In Everything We Do Looking for hemp-derived CBD ingredients of the highest quality, purity and consistency? Need a proven source for premium bulk and differentiated finished goods, whose mandate to champion innovation, science and compliance leads the field? Explore how the beneficial properties of CBD can enhance your product’s impact and value — in food and beverage, creams and other topicals, pet products and more. Trust a genuine industry pioneer. Partner with GenCanna. Since our inception in 2014, GenCanna has remained at the vanguard of today’s now booming CBD industry, because our influential founders helped create it. Literally. Vetted, tested and proven over time, this makes us your smartest, surest choice in a full-service CBD partner. Our roots extend back to the earliest days of cannabis legalization and reform. GenCanna helped lead the introduction of Kentucky’s groundbreaking 2014 Hemp Pilot Program. We continue spearheading regulatory initiatives that open and accelerate industry growth. In short, GenCanna has remained at the heart of it all, earning the highest industry certifications, product validations and compliance accreditations to this day. Our scalable, premium-quality derivatives and differentiated finished goods bear witness to GenCanna’s unbridled commitment to excellence: • High-Quality Cannabinoid Isolates and Distillates • Premium Bulk Broad-Spectrum and Full-Spectrum Ingredients • Water-Soluble Liquids and Soluble Powders • Reserve Oils and Bottled Custom Oil Drops • Superior Custom Formulations: -Gummies -Capsules, soft gels, tablets, and other supplement form factors -Food and beverages -Broad range of cosmetics and topicals -Health and wellbeing topicals -Pet products • Turnkey Private Label Programs • White Label Products … you name it, we’ll infuse it! Ready to achieve the next level in CBD success? RELIABLE. INNOVATIVE. GENCANNA. Premium CBD ingredients that formulate profitability for you.

Givaudan is a global leader in Fragrance & Beauty and Taste & Wellbeing. We celebrate the beauty of human experience by creating for happier, healthier lives with love for nature. Together with our customers we deliver food experiences, craft inspired fragrances, and develop beauty and wellbeing solutions that make people look and feel good. With over 163 locations in 52 countries and over 78 production sites, of which 31 are located in Europe, 22 in North America, 17 in Latin America, 8 in Asia-Pacific, and 1 across South Asia, the Middle East, and Africa, we are committed to driving purpose-led growth that makes a positive impact. Givaudan: Human by nature. www.givaudan.com

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia. BIO 300 is also under development for inflammatory lung diseases with an immediate focus on mitigation of pulmonary injury due to COVID-19. A recent contract from NIAID will fund a phase 2 study on BIO 300 in recovering COVID patients in an effort to stem progressive long-term lung complications, such as fibrosis. BIO 300 was licensed from the US Department of Defense, where it was originally developed to prevent injuries associated with ionizing radiation. This program is still underway with a focus on prevention of acute radiation syndrome as well as lung injury. For more information about Humanetics, please visit our corporate website at www.humaneticscorp.com.

Jeil Pharmaceutical - Founded in 1959, Jeil has developed and supplied superior pharmaceutical products to promote the happiness and health of mankind and has contributed to the growth and development of the pharmaceutical industry in Korea. Jeil has been listed on KOSPI since 1988. As of 2018, Jeil is constituted of 1143 employees and has sales amount reaching above 680 billion Korean wons. The Central R&D Center established in 1980 forms the core of the R&D activities of Jeil. Currently, as of 2018, the new drug development laboratory, the pharmacology & toxicology laboratory, the organic synthesis laboratory, the formulation laboratory, and the analysis laboratory are actively engaged in conducting research into the complete manufacture and ingredients of innovative new drugs, incrementally modified drugs, and generic drugs. Jeil’s factory established in 1986 and located in Yongin-si, Korea was accredited as fulfilling KGMP in 1987, and produces tablets, capsules, injections, finished pharmaceutical products including patches, and Active Pharmaceutical Ingredients(APIs) such as anti-biotic ingredients, etc. The construction of new factory with the most up-to-dated facilities, which complies with EU-GMP and US-GMP, has been completed in 2016. In May of 2018, Jeil established Pharmaceutical Technology Research Institute, a formulation and analysis lab, at Yongin Technovalley in Yongin-si, Korea to further improve and invest in research and development of Incrementally Modified Drug (IMD) and generic products. Jeil, equipped with global-class research centers and production facilities, has been recognized for its outstanding value on the world market as well. In the ingredients sector, Jeil exports synthetic ingredients such as Cefditoren Pivoxil, Epinastine HCl, etc. to Japan and China, while also supplies finished products such as Kefentech Plaster (Ketoprofen), Cilapenem Injection (Imipenem / Cilastatin Sodium), etc. to more than 40 countries in ASEAN, Central and South America, Africa, etc. Within the South Korean market, Jeil operates a well-trained MR organization to cover the nation-wide market based on science and evidence, and thereby has become a supplier of over 70 prescription drugs and over 30 over-the-counter drugs. Beginning in the period between 1970 and 1980, Jeil has engaged in technological partnerships (licensing) with global pharmaceutical companies to provide the domestic market with outstanding new drugs. It has also been the first Korean company to engage in co-promotion successfully with the globally renowned company Pfizer, executing a win-win strategy with our overseas collaborative partners and thus winning recognition as an advanced pharmaceutical company adapted to internationalized business practices. We thank all of the visitors to our Jeil’s homepage for their interest and encourage you to contact us for further business progress.

Mapi Pharma is a late clinical stage pharmaceutical company, currently in the final stage of the Phase III with its lead product, GA Depot, a long-acting depot glatiramer acetate for treating MS and has several generic commercialized products. Mapi is engaged in the development of high barrier-to-entry and high added-value life cycle management products that target large markets and high barrier patented generic drugs that include complex API and formulations. The GA Depot injection, administered once every four weeks, is the first in a series of depot long-acting injections in the company's pipeline. The product is a long-acting version of Copaxone®. Mapi partnered with Mylan/Viatris Inc. (NASDAQ: VTRS) for GA Depot in an agreement under which Mylan was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis. Mapi is also in the midst of a Phase II with GA Depot for PPMS and has a pipeline of long acting depot including GLP-1 for treating diabetes and Parkinson's disease for which we are looking for strategic partners. Mapi is built on strong chemical and pharmaceutical R&D capabilities focused on long acting depot technologies and combination treatments including loaded exosomes derived from adipose tissue. Mapi is headquartered in Israel, with R&D facilities in Israel, an API production facility in the Neot-Hovav Eco Industrial Park and an aseptic manufacturing and a large scale Fill & Finish facility for injectable Finished Dosage Forms in Jerusalem totaling 45,000 ft2. Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

Matrix Biomed, Inc. is a biopharmaceutical company focused on delivering gene-based therapeutics. Gene-based therapeutics are directed to address both the dysregulation of multiple genes as well as their interactions in gene regulatory networks. Only by addressing the dysregulation of multiple genes and their interactions in gene regulatory networks, Matrix Biomed, Inc. is able to deliver a therapy designed to truly revert a disease state to healthy state. Currently, Matrix Biomed, Inc. gene-based therapeutics are directed to therapies and drug products to make cancer treatment more manageable and successful through the elimination of the dose-limiting, life-threatening, and treatment-inhibiting toxicities associated with chemotherapy and radiotherapy while targeting the master genes responsible for cancer growth and development, hypoxia inducible factor -1 (HIF-1) and hypoxia inducible factor-2 (HIF2).

NATCO Pharma is a vertically integrated company dedicated to the development, manufacture, and supply of pharmaceutical and agrochemical products. Established with the mission to make specialty medicines accessible to all, we are rooted in integrity, respect, openness, collaboration, creativity, and quality. Founded in 1981, we now have a strong global presence in over 50 countries. NATCO has emerged as an esteemed pharmaceutical company with a presence in Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs) in both domestic and international markets. NATCO Pharma's focused approach has led to expanded capabilities across diverse therapy segments, particularly in oncology. We operate in two key segments: Pharmaceuticals and Agrochemicals. Our expertise excels in the FDF division, crafting intricate pharmaceutical solutions tailored to specific therapeutic needs. In the manufacturing of APIs, we maintain high quality and adhere to all regulatory standards with a focus on innovation. In the Crop Health Sciences (CHS) division, we produce high-value agricultural input products to meet farmers' demands, including environmentally safer biocontrol products. Operating globally, NATCO's work contributes to its diverse market presence. NATCO believes in sustainable and balanced growth through the synergy of our talented workforce and an innovative culture. We are dedicated to maximizing shareholder value creation through innovation, employee engagement, process and system optimization.

Oncorena is aiming to save human lives by transforming a natural substance into a breakthrough therapy treatment for advanced kidney cancer. We have completed all preclinical studies and are moving into early-stage clinical development. The objective is to confirm the powerful anti-tumor activity of our drug candidate - based on the natural substance orellanine - in advanced kidney cancer patients. Oncorena AB is headquartered in Lund, Sweden.

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit: www.parabilismed.com